Gordon Dunn bought $23k of QNRX
Chief Financial Officer at Quoin Pharmaceuticals, Ltd.. 28,856 shares at an average of $0.80, traded Sep 9, 2024, filed Sep 11, 2024.
Score components
- +22RoleCFO
- 0Trade size$23k at market
- +8Relative to holdingsFirst purchase: no shares before this trade
- +8Price context83% below the 52-week high
- +15Cluster3 insiders buying within 14 days
- 0Repeat buyingFirst buy in 90 days
- 0Track recordToo few past buys to judge (1 with prices)
What happened after comparable buys
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m -23.2%, 3m +13.7%, 6m -56.1%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001104659-24-098940, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Sep 9, 2024 | POpen-market purchase Ordinary Shares | +856 | $0.80 | $685 | 856 | Sep 11, 2024 |
| Sep 9, 2024 | POpen-market purchase Ordinary Shares | +4,000 | $0.78 | $3,120 | 4,856 | Sep 11, 2024 |
| Sep 9, 2024 | POpen-market purchase Ordinary Shares | +4,000 | $0.80 | $3,200 | 8,856 | Sep 11, 2024 |
| Sep 10, 2024 | POpen-market purchase Ordinary Shares | +10,000 | $0.91 | $9,100 | 18,856 | Sep 11, 2024 |
| Sep 10, 2024 | POpen-market purchase Ordinary Shares | +10,000 | $0.71 | $7,100 | 28,856 | Sep 11, 2024 |
Related signals
Other insiders at Quoin Pharmaceuticals, Ltd. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 55Moderate | Quoin Pharmaceuticals, Ltd. | Denise P. Carter Chief Operating Officer | $100k 20,490 shares | +119% | |
| 38Weak | Quoin Pharmaceuticals, Ltd. | Anthony James Culverwell director | $30k 6,146 shares | +18% | |
| 54Moderate | Quoin Pharmaceuticals, Ltd. | Sally Bridget Lawlor Chief Financial Officer | $50k 10,244 shares | +2328% | |
| 60Notable | Quoin Pharmaceuticals, Ltd. | Michael Myers Chief Executive Officer | $100k 20,490 shares | +119% | |
| 44Moderate | QNRXbuy Quoin Pharmaceuticals, Ltd. | Dennis Langer director | $129k 15,152 shares | first purchase | |
| 58Moderate | Quoin Pharmaceuticals, Ltd. | Denise P. Carter Chief Operating Officer | $250k 555,556 shares | +1180% | |
| 46Moderate | Quoin Pharmaceuticals, Ltd. | Anthony James Culverwell director | $45k 100,000 shares | first purchase | |
| 54Moderate | Quoin Pharmaceuticals, Ltd. | Gordon Dunn Chief Financial Officer | $55k 122,221 shares | +424% | |
| 63Notable | Quoin Pharmaceuticals, Ltd. | Michael Myers Chief Executive Officer | $250k 555,556 shares | +1176% | |
| 58Moderate | Quoin Pharmaceuticals, Ltd. | Denise P. Carter Chief Operating Officer | $29k 37,735 shares | +403% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.